Clinical Trial Update: VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features [Phase 2]

View source ↗

Summary

Phase 2 trial of Velcade (bortezomib) in previously treated stage IIIB/IV bronchioloalveolar carcinoma and BAC-featured adenocarcinoma of the lung was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Bronchioloalveolar Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar | Phase 2 | Status: TERMINATED